Denali Therapeutics
DNLI
190 hedge funds and large institutions have $2.8B invested in Denali Therapeutics in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 68 increasing their positions, 69 reducing their positions, and 40 closing their positions.
0.82% more ownership
Funds ownership: 69.82% → 70.64% (+0.82%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 69
11% less funds holding
Funds holding: 213 → 190 (-23)
26% less capital invested
Capital invested by funds: $3.8B → $2.8B (-$998M)
53% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 40
55% less call options, than puts
Call options by funds: $818K | Put options by funds: $1.8M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$27.5M |
| 2 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$23.4M |
| 3 |
Bank of New York Mellon
New York
|
+$23.3M |
| 4 |
Morgan Stanley
New York
|
+$14.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.91M |
Top Sellers
| 1 |
BAMCO Inc
New York
|
-$11.7M |
| 2 |
Jennison Associates
New York
|
-$10M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$9.67M |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
-$8.41M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$7.95M |
DNLI Hedge Fund Activity: Q1 2022 in Review
190 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2022, worth a combined $2.8B — down 26% from $3.8B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of DNLI and 19 opened new positions — a net loss of 21 holders — while 69 trimmed existing stakes and 68 added.
The largest buyer was State Street, adding an estimated $27.5M. The largest seller was BAMCO Inc, cutting an estimated $11.7M.
- 190 institutional investors held Denali Therapeutics (DNLI) as of Q1 2022, down from 213 in Q4 2021.
- Funds reported $2.8B of Denali Therapeutics stock for Q1 2022, down 26% quarter-over-quarter.
- 19 funds opened new Denali Therapeutics positions in Q1 2022 and 40 closed out, a net change of -21 holders.
- The largest Denali Therapeutics buyer in Q1 2022 was State Street, an estimated $27.5M added.
- The largest Denali Therapeutics seller in Q1 2022 was BAMCO Inc, an estimated $11.7M sold.
Based on aggregated 13F filings for Q1 2022.